Page 51 - Read Online
P. 51
Page 336 Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37
Ref. [24] [38] [65] [13] [14] [59] [27] [22] [24]
Clinical outcomes No association of ABCG2 No association of ABCG2 c.421C>A variant with DGF or AR - No association of SLCO1B1 *1A, *1B and *15 variants with diarrhea SLCO1B1 c.521C allele was associated with reduced MPA-related adverse events, on cyclosporine-free treatment - No association of SLCO1B1 c.388A>G and c.521T>C variants with No association of SLCO1B1 rs4149056 and rs11045819 variants with leukopenia No association o
Pharmacokinetics c.421C>A variant with No association of ABCG2 c.421C>A and rs4491984 variants with MPA C/D (days 3-8) No association of SLCO1B1 *1A, *1B and *15 variants with MPA pharmacokinetics - No association of SLCO1B1 c.388A>G, 463C>A and c.521T>C variants with MPA or MPAG pharmacokinetics No association of SLCO1B1 c.388A>G and c.521T>C variants with exposure to MPA, MPAG diarrhea or leukopenia or AcMPAG - - No assoc
Immunosuppressive regimen EC-MPS Tacrolimus Corticosteroids One-year MPA C/D follow-up MMF Cyclosporine Tacrolimus Corticosteroids 40-day follow-up MMF Tacrolimus Corticosteroids At day 28 MMF Cyclosporine Tacrolimus mTOR inhibitor Corticosteroids One-year follow-up MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids At a point between 3-6 months MMF Cyclosporine Tacrolimus Corticosteroids One-year follow-up MMF Cyclo
Population 97 adult patients (Brazil) 408 adult patients (China) 87 adult patients (Japan) (France) 185 patients (France) 338 adult patients 284 pediatric and young adult patients (USA) 145 adult patients (Brazil) 97 adult patients (Brazil)
Study design Prospective Retrospective Prospective Retrospective (Transgene 218 adult patients study) Prospective (included multicenter Apomygre study) Prospective (FDCC Study) Retrospective (Case- Control), multicenter Retrospective (Case- control) Prospective
Allele frequency c.421A: 10% c.421A: 31% rs4491984A: 50% SLCO1B1*1A: 32% SLCO1B1*1B: 50% SLCO1B1*15: 18% -11187A: 6% c.388A: 50% c.521C: 14% c.388G: 44% 463A: 14% c.521C: 18% c.388G: 46% c.521C: 17% - c.521C: 20% c.388A: 44% c.521C: 14%
Variant rs2306283 (c.388A>G) (c.521T>C or Val174Ala)
rs4149015 (-11187G>A) rs11045819 (463C>A) rs4149056 rs11045819 (Pro155Thr)
Gene SLCO1B1